Mayo Clinic developed an AI that analyzes routine pathology slides to classify meningiomas and predict recurrence risk, reducing dependency on advanced genetic testing.
Key Details
- 1Study published in The Lancet Digital Health by Mayo Clinic researchers.
- 2AI models analyze standard H&E slides to classify meningiomas and predict recurrence.
- 3Approach relies on images already used in clinical care, not on expensive genetic tests.
- 4Dataset included tissue samples, images, and clinical data from 672 patients.
- 5AI predictions remained valuable beyond traditional clinical factors like tumor grade or patient age.
- 6Further prospective studies are needed before routine clinical adoption.
Why It Matters
This work shows how imaging AI can extend the power of pathology slides, making advanced tumor insights more universally accessible even where genetic testing isn't available. It holds promise for improved, personalized cancer care using existing imaging workflows.
Source
EurekAlert
Related News
•EurekAlert
New Daydreaming Algorithm Boosts Neural Networks' Recall of Biased Image Data
Researchers unveil a new 'Centered Daydreaming' algorithm enabling AI to effectively learn and recall from imbalanced, real-world image data.
•EurekAlert
Polymer-Based Flexible Wireless Sensors: AI-Driven Health Monitoring Review
A major review highlights how advanced polymer-based flexible wireless sensors, enhanced by AI-driven data processing, can transform continuous physiological health monitoring.
•EurekAlert
PET Imaging Uncovers Synaptic Loss Patterns in Schizophrenia
A major PET imaging study reveals widespread, non-random synaptic loss in schizophrenia, distinct from brain volume changes seen on MRI.